Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort-Reference-Cited by-同舟云学术

Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

Published:2023-02-10 Issue:2 Volume:12 Page:529-542
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Pelle Juliette,Briant Anais R.,Branger Pierre,Derache Nathalie,Arnaud Charlotte,Lebrun-Frenay Christine,Cohen Mikael,Mondot Lydiane,De Seze Jerome,Bigaut Kevin,Collongues Nicolas,Kremer Laurent,Ricard Damien,Bompaire Flavie,Ohlmann Charlotte,Sallansonnet-Froment Magali,Ciron Jonathan,Biotti Damien,Pignolet Beatrice,Parienti Jean-Jacques,Defer Gilles^ORCID

Funder

Caen University Hospital

Biogen

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-023-00440-5.pdf

Reference30 articles.

1. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing–Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–60.

2. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15–23.

3. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.

4. Butzkueven H, Kappos L, Wiendl H, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry. 2020;91:660–8.

5. Horakova D, Uher T, Krasensky J, et al. Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: a longitudinal, retrospective study. Mult Scler Relat Disord. 2020;46:102543.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis;Acta Neurologica Belgica;2024-03-08